GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
12.10
0.00 (0.00%)
Aug 8, 2025, 9:35 AM - Market open

Company Description

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.

Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression.

The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.

The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC
GH Research logo
CountryIreland
Founded2018
IPO DateJun 25, 2021
IndustryBiotechnology
SectorHealthcare
Employees50
CEOVelichka Valcheva

Contact Details

Address:
Joshua Dawson House, Dawson Street
Dublin, D02 RY95
Ireland
Phone353 1 437 8334
Websiteghres.com

Stock Details

Ticker SymbolGHRS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001855129
CUSIP NumberG3855L106
ISIN NumberIE000GID8VI0
SIC Code2834

Key Executives

NamePosition
Dr. Velichka Valcheva M.D., M.Sc.Chief Executive Officer
Florian Schonharting M.Sc. (Econ)Co-Founder and Non-Executive Chairman of the Board
Magnus HalleCo-Founder and MD of Ireland
Julie Ryan F.C.A.Vice President of Finance
Aaron Cameron M.B.A.Chief Operating Officer

Latest SEC Filings

DateTypeTitle
Aug 7, 20256-KReport of foreign issuer
Aug 6, 2025SCHEDULE 13G/AFiling
Aug 1, 20256-KReport of foreign issuer
Jul 29, 202520-F/AFiling
Jul 23, 20256-KReport of foreign issuer
Jun 20, 20256-KReport of foreign issuer
Jun 18, 20256-KReport of foreign issuer
Jun 13, 20256-KReport of foreign issuer
May 27, 20256-KReport of foreign issuer
May 21, 20256-KReport of foreign issuer